Literature DB >> 15813424

Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment.

M N Efde1, P M Houtman, J P L Spoorenberg, T L T A Jansen.   

Abstract

This case report describes a 61-year-old rheumatoid arthritis patient with an atypical clinical presentation of a sore throat. Because of rheumatoid arthritis refractory to conventional disease-modifying antirheumatic drug therapy, anti-TNFalpha was felt to be indicated, and a screening for tuberculosis was carried out. As the screening for tuberculosis (PPD) was positive, isoniazid was prescribed prophylactically for six months. After eight months of anti-TNFalpha (adalimumab) treatment, he developed tonsillar enlargement and nodular pulmonary lesions. Histopathological and microbial investigations established the diagnosis of tonsillar tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813424

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  3 in total

1.  Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab.

Authors:  Valdeŕilio Feijó Azevedo; C Parchen; S A Coelho; D C Lacerda; C G Hirth
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

2.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

Review 3.  Primary tonsillar tuberculosis in a pediatric patient: Case report and literature review.

Authors:  Stefana Maria Moisa; Ingrith Miron; Anca Adam-Raileanu; Vasile Valeriu Lupu; Ancuta Lupu; Elena Tarca
Journal:  Medicine (Baltimore)       Date:  2021-11-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.